Despite considerable challenges, RNA interference (RNAi) as a therapeutic strategy continues to draw excitement and scrutiny. Two recent meetings—Select Biosciences’ “RNAi and miRNA World Congress” ...

Most siRNA oligonucleotides (oligos) for in vivo use are chemically synthesized duplexes of 21 to 23 oligos based on the original work of Tuschl and colleagues. 4, 5 Although chemical modifications ...

Despite the Nobel Prize-winning discovery of RNA interference (RNAi) over a decade ago and the billions of dollars spent developing therapeutic applications, delivery issues continue to challenge the ...

Partnership launched under MTEA to evaluate the potential of Vect-Horus technology to deliver siRNAs into the CNSAssessment ...

Alnylam has set out how it plans to deliver siRNA to the central nervous system and other tissues beyond the liver. Writing in Nature Biotechnology, the RNA specialist shared details of how the ...

“The copious patentable aspects of a therapeutically efficacious siRNA delivery formulation imply intense patenting activity in the years to come, along with market exclusivity that can be extended ...

A "gene silencer" (technically known as small interfering RNA, or siRNA), locally delivered by nanoparticles embedded in an injectable gel produced through 3D printing, can switch off the defective ...

Researchers engineered RNA micelles carrying gemcitabine, survivin-targeting siRNA and a tumor-binding ligand. In mice with ...

OliX Pharmaceuticals is joining hands with the French bio corporations "VECT-Horus" to verify delivery technology for short interfering RNA (siRNA) therapies for central nervous system (CNS) diseases.